Toxicities associated with immunotherapies for hematologic malignancies

Mark B Leick; Marcela V Maus

doi:10.1016/j.beha.2018.03.004

Toxicities associated with immunotherapies for hematologic malignancies

Best Pract Res Clin Haematol. 2018 Jun;31(2):158-165. doi: 10.1016/j.beha.2018.03.004. Epub 2018 Mar 28.

Authors

Mark B Leick¹, Marcela V Maus²

Affiliations

¹ Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
² Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: [email protected].

PMID: 29909916
DOI: 10.1016/j.beha.2018.03.004

Abstract

Immunotherapy has generated tremendous hope for patients with cancer that is refractory to standard approaches. Hematologic malignancies have taken the lead in harnessing the most recent advances in cell-based immunotherapies, such as CAR T cells, and some patients have achieved durable remissions. However, these T-cell-engaging therapies are associated with a new set of toxicities which need to be managed by caretakers, oncologists, nurses, and healthcare staff. In this review we provide an overview of the toxicity of some of these revolutionary agents including bispecific T cell engagers, checkpoint inhibitors, chimeric antigen receptor T-cells.

Keywords: CAR-T; Cellular therapy; Immunotherapy; Toxicity.

Publication types

Review

MeSH terms

Hematologic Neoplasms* / immunology
Hematologic Neoplasms* / pathology
Hematologic Neoplasms* / therapy
Humans
Immunotherapy, Adoptive / methods*
Receptors, Chimeric Antigen* / immunology
Receptors, Chimeric Antigen* / therapeutic use

Substances

Receptors, Chimeric Antigen